Effect of Combined Antisense Oligodeoxynucleotides Directed against the Human Papillomavirus Type 16 on Cervical Carcinoma Cells

Archives of Medical Research

Volumn 38, Issue 7, 2007, Pages 730-738

  Márquez Gutiérrez, Miguel A ^a   Benítez Hess, María L ^a   DiPaolo, Joseph A ^b   Alvarez Salas, Luis M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antisense; Cervical carcinoma; Gene therapy; Oligodeoxynucleotides; Papillomavirus

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; PROTEIN E6; PROTEIN E7; RIBONUCLEASE H;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN DEGRADATION; RIBONUCLEASE PROTECTION ASSAY; UTERINE CERVIX CARCINOMA; VIRUS GENOME;

CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; HUMAN PAPILLOMAVIRUS 16; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 34548406407     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.04.011     Document Type: Article

References (45)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. [see comments]. J Pathol 189 (1999) 12-19
2. Carbone M., Klein G., Gruber J., and Wong M. Modern criteria to establish human cancer etiology. Cancer Res 64 (2004) 5518-5524
3. Dürst M., Gissmann L., Ikenberg H., and Zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
4. Herrington C.S. Do HPV-negative cervical carcinomas exist?-revisited. J Pathol 189 (1999) 1-3
5. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
6. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
7. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
8. Hubbert N.L., Sedman S.A., and Schiller J.T. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66 (1992) 6237-6241
9. Dyson N., Howley P.M., Münger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
10. Münger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 (2001) 7888-7898
11. Münger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 89 (2002) 213-228
12. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110 (2006) 525-541
13. Alvarez-Salas L.M., Benitez-Hess M.L., and DiPaolo J.A. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses. Antivir Ther 8 (2003) 265-278
14. Icenogle J.P., Sathya P., Miller D.L., Tucker R.A., and Rawls W.E. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 184 (1991) 101-107
15. Alvarez-Salas L.M., Wilczynski S.P., Burger R.A., Monk B.J., and DiPaolo J.A. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int J Oncol 7 (1995) 261-266
16. Yamada T., Wheeler C.M., Halpern A.L., Stewart A.C., Hildesheim A., and Jenison S.A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69 (1995) 7743-7753
17. Wheeler C.M., Yamada T., Hildesheim A., and Jenison S.A. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol 35 (1997) 11-19
18. Pang T., Hu X., and Ponten J. Sequence variations of the late upstream region of HPV16 in cervical intraepithelial neoplasm and invasive carcinoma. Int J Gynecol Cancer 12 (2002) 99-104
19. Vaeteewoottacharn K., Jearanaikoon P., and Ponglikitmongkol M. Co-mutation of HPV16 E6 and E7 genes in Thai squamous cervical carcinomas. Anticancer Res 23 (2003) 1927-1931
20. De la Cruz-Hernandez E., Garcia-Carranca A., Mohar-Betancourt A., Duenas-Gonzalez A., Contreras-Paredes A., Perez-Cardenas E., et al. Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J Gen Virol 86 (2005) 2459-2468
21. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75 (1978) 285-288
22. Maher L.J., and Dolnick B.J. Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleoside methylphosphonates in a cell-free system. Nucleic Acids Res 16 (1988) 3341-3358
23. Walder R.Y., and Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85 (1988) 5011-5015
24. Agrawal S., and Zhao Q. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev 8 (1998) 135-139
25. Agrawal S., and Kandimalla E.R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets 1 (2001) 197-209
26. Alvarez-Salas L.M., Cullinan A.E., Siwkowski A., Hampel A., and DiPaolo J.A. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci USA 95 (1998) 1189-1194
27. Venturini F., Braspenning J., Homann M., Gissmann L., and Sczakiel G. Kinetic selection of HPV 16 E6 /E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res 27 (1999) 1585-1592
28. Alvarez-Salas L.M., Arpawong T.E., and DiPaolo J.A. Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense Nucleic Acid Drug Dev 9 (1999) 441-450
29. Benitez-Hess M.L., DiPaolo J.A., and Alvarez-Salas L.M. Antisense activity detection by inhibition of fluorescence resonance energy transfer. Luminescence 19 (2004) 85-93
30. Guapillo M.R., Marquez-Gutiérrez M.A., Benitez-Hess M.L., and Alvarez-Salas L.M. A bacterial reporter system for the evaluation of antisense oligodeoxynucleotides directed against human papillomavirus type 16 (HPV-16). Arch Med Res 37 (2006) 584-592
31. Levy J.A. Demonstration of differences in murine sarcoma virus foci formed in mouse and rat cells under a soft agar overlay. J Natl Cancer Inst 46 (1971) 1001-1007
32. Dodson M.G., Slota J., Lange C., and Major E. Distinction of the phenotypes of in vitro anchorage-independent soft-agar growth and in vivo tumorigenicity in the nude mouse. Cancer Res 41 (1981) 1441-1446
33. Anderson S., Shera K., Ihle J., Billman L., Goff B., Greer B., et al. Telomerase activation in cervical cancer. Am J Pathol 151 (1997) 25-31
34. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 (1998) 84-88
35. Bilanges B., and Stokoe D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 388 (2005) 573-583
36. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin Biol Ther 4 (2004) 1251-1264
37. Bernard H.U., Calleja-Macias I.E., and Dunn S.T. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 118 (2006) 1071-1076
38. Ho L., Chan S.Y., Chow V., Chong T., Tay S.K., Villa L.L., and Bernard H.U. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J Clin Microbiol 29 (1991) 1765-1772
39. Calleja-Macias I.E., Kalantari M., Huh J., Ortiz-Lopez R., Rojas-Martinez A., Gonzalez-Guerrero J.F., et al. Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 319 (2004) 315-323
40. Mathews D.H., and Turner D.H. Dynalign: an algorithm for finding the secondary structure common to two RNA sequences. J Mol Biol 317 (2002) 191-203
41. Ruiz J., Wu C.H., Ito Y., and Wu G.Y. Design and preparation of a multimeric self-cleaving hammerhead ribozyme. Biotechniques 22 (1997) 338-345
42. Lavigne C., Yelle J., Sauve G., and Thierry A.G. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication. AAPS PharmSci 3 (2001) E7
43. el Awady M.K., El Din N.G., El Garf W.T., Youssef S.S., Omran M.H., El Abd J., et al. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. Cancer Cell Int 6 (2006) 18-26
44. Palacio-Mejia L.S., Rangel-Gomez G., Hernandez-Avila M., and Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex 45 (2003) S315-S325
45. Lowy D.R., and Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 116 (2006) 1167-1173